BASILEAPHARMA.ORG

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

http://www.basileapharma.org/

OVERVIEW OF basileapharma.org

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

0

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR BASILEAPHARMA.ORG

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

April

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Wednesday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 13 reviews

5 star

4

4 star

5

3 star

3

2 star

0

1 star

1

Hey there! Start your review of basileapharma.org

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

FAVICON PREVIEW

16x16

CONTACTS AT BASILEAPHARMA.ORG

Roland Weiss

Basileapharma Ltd

Grenzac●●●●●●●sse 487

Ba●●el , BS, 4058

CH

41.6●●●●1111

41.6●●●●1112

ro●●●●●●●●●●@basileapharma.com

View this contact

Basilea Pharmaceutica Ltd

Domain Admin

Grenzac●●●●●●●sse 487

Ba●●el , Basel, 4005

GB

41.6●●●●1111

41.6●●●●1112

do●●●●●●●●●@basileapharma.com

View this contact

NetNames USA Inc.

Netnames USA Hostmaster

NetNam●●●●●●A Inc.

New●●●ork , n/a, NY 10014

US

44.2●●●●4599

44.2●●●●5744

te●●@netnamesusa.com

View this contact

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

DOMAIN REGISTRATION INFORMATION

REGISTERED: n/a
UPDATED: 2014 April 09
EXPIRATION: EXPIRED REGISTER THIS DOMAIN

BUY YOUR DOMAIN

NAME SERVERS

1: ns2.netnames.net
2: ns1.netnames.net

REGISTRAR

Ascio Technologies, Inc. Danmark - Filial af Ascio technologies, Inc. USA (R76-LROR)

WHOIS : whois.publicinterestregistry.net

REFERRED :

CONTENT

PAGES IN
THIS WEBSITE

0

SSL

EXTERNAL LINKS

0

SITE IP

54.246.175.25

LOAD TIME

0 sec

SCORE

6.2

PAGE TITLE

Basilea Pharmaceutica - Home | basileapharma.org Reviews

<META> DESCRIPTION

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

<META> KEYWORDS

1 biotechnology company

2 discovery

3 development

4 novel drugs

5 unmet medical needs

6 anti-bacterials

7 anti-fungals

8 dermatology

9

10 coupons

CONTENT

Page content here

KEYWORDS ON PAGE

site map,quick links,e mail distribution,ad hoc notices,financial reports,corporate calendar,corporate,corporate information,board of directors,dr martin nicklasson,mr domenico scala,prof daniel lew,dr thomas werner,board committees,management committee

SERVER

Apache

POWERED BY

PHP/5.5.9-1ubuntu4.17

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

Basilea Pharmaceutica - Home | basileapharma.org Reviews

https://basileapharma.org

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

OTHER SITES

basileanticapasticceria.it

Prodotti Dolciari da Forno tipici del Salento - Pasticceria da Forno

Prodotti dolciari da Forno tipici del Salento - Pasticceria da Forno - Prodotti Dolciari. PRODOTTI DOLCIARI - PASTICCERIA DA FORNO DAL 1889. FIOR DÌ MANDORL A. Prodotti - Pasta di Mandorle. Croccante alle Mandorle Bianche. Croccante alle Mandorle Nere. I Tondi al Cioccolato. Ricci di Mandorla alle Cigliege Rosse. Ricci di Mandorla al Caffè. Ricci di Mandorla alle Mandorle. Ricci di Mandorla alle Cigliege Verdi. Ricci di Mandorla al Cacao a Mandorle. Ricci di Mandorla Misti. Ricci di Mandorla Quaresimali.

basileapharma.biz

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.com

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.info

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.net

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.org

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharma.us

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.biz

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.ch

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.com

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...

basileapharmaceutica.info

Basilea Pharmaceutica - Home

Mr Hans-Beat Gürtler. Dr Thomas M. Rinderknecht. Mr Steven D. Skolsky. Transparence des liens d’intérêt. How to find us. Investor Relations / Media. Rsaquo;› go! Go to Annual report 2014. Link to Share Information. Monday, May 04. 2015. Basilea reports start of first-in-human phase 1 oncology study with oral panRAF kinase inhibitor. Wednesday, April 29. 2015. Basilea shareholders approve all resolutions proposed by the Board of Directors at the Ordinary General Meeting of Shareholders. Basel, Switzerland...